SEVERE ASTHMA

Which of your patients with severe asthma and type 2 inflammation are at an increased risk of exacerbations?

Woman with dark curly hair wearing a tan jacket while waiting at a train station

Type 2 inflammation drives risk of asthma exacerbations

Up to 84% of patients with severe asthma had evidence of an eosinophilic phenotype, a key marker of TYPE 2 INFLAMMATION.1* This is a risk factor for uncontrolled symptoms and exacerbations.2,3

>50% of patients with severe asthma were uncontrolled on current treatments.4,5†‡

Recent exacerbations are a strong predictor of a patient’s future exacerbation risk, making exacerbation prevention critical to asthma management.2,6

  • *

    Evidence of eosinophilic phenotype in 74%-84% of patients. International Severe Asthma Registry (ISAR): 84% of adults identified as “most likely” to have an eosinophilic phenotype in the prospective analysis (N=1716) using a predefined algorithm: ≥1: blood eosinophil count ≥300 cells/µL anti-cytokine/cytokine-receptor therapy; blood eosinophil count ≥150-300 cells/µL with maintenance OCS; or ≥2 of nasal polyps, elevated FeNO, late-onset asthma. 74% identified in retrospective analysis of medical records in the US (N=1891).1

  • †

    The ISAR collected data prospectively and retrospectively from 4990 adults with severe asthma receiving GINA Step 5 treatment or with uncontrolled asthma at GINA Step 4 from the US, UK, South Korea, Italy, Australia, Singapore, and New Zealand (December 2014-2017). 57.2% of patients had poorly controlled asthma defined as ACQ-5>1.5 at entry.4

  • ‡

    US National Health and Wellness Survey data (2011-2013) from 1923 adults with physician-diagnosed asthma on ICS/LABA with ≥1 allergic comorbidity. 54.4% had very poorly controlled or not-well controlled asthma as defined by ACT <20.5

Who is the EXDENSUR patient?

Patient characteristics:

  • Diagnosed with severe asthma
  • Type 2 inflammation characterized by BEC: ≥150 cells/µL at screening or ≥300 cells/µL in the previous 12 months
  • History of 2 clinically significant exacerbations* in the past year

Current treatment:

  • Medium- to high-dose ICS + another controller (eg, LABA)

Patient complaints2:

  • Nighttime awakenings 1-2x per week due to shortness of breath
  • Persistent coughing and wheezing
  • Uses rescue inhaler twice or more per week
  • *

    Defined as worsening of asthma requiring treatment with systemic corticosteroids (IV or oral for ≥3 days or single IM dose) or hospitalization or ED visit; or at least double the existing maintenance systemic corticosteroid dose for ≥3 days.

ACQ-5=Asthma Control Questionnaire (5-item); ACT=Asthma Control Test; BEC=blood eosinophil count; ED=emergency department; FeNO=fractional exhaled nitric oxide; GINA=Global Initiative for Asthma; ICS=inhaled corticosteroid; IM=intramuscular; IV=intravenous; LABA=long-acting beta2-agonist; OCS=oral corticosteroid.

For patients like these, it may be time to think EXDENSUR for add-on treatment

Consider EXDENSUR—designed to be ultra-long-acting with just 1 dose every 6 months

SEE HOW IT WORKS

More to explore:

Efficacy data

Explore results from phase 3 clinical trials.

VIEW DATA

Access & Support

Find support materials and insurance information to help your patients access EXDENSUR.

LEARN ABOUT PATIENT ACCESS

Indication & Safety Info

Indication

Important Safety Information

Indication

EXDENSUR is indicated for the add-on maintenance treatment of severe asthma, characterized by an eosinophilic phenotype, in adult and pediatric patients aged 12 years and older. EXDENSUR is not indicated for the relief of acute bronchospasm or status asthmaticus.

Important Safety Information

WARNINGS AND PRECAUTIONS

Hypersensitivity Reactions
Hypersensitivity reactions, including anaphylaxis, can occur following administration of EXDENSUR. If a hypersensitivity reaction occurs, discontinue EXDENSUR and initiate appropriate therapy.

Acute Asthma Symptoms or Deteriorating Disease
EXDENSUR should not be used to treat acute asthma symptoms or acute exacerbations.

Risk Associated with Abrupt Reduction of Corticosteroid Dosage
Upon initiation of EXDENSUR therapy, do not abruptly discontinue systemic or inhaled corticosteroids. Reductions in corticosteroid dose, if appropriate, should be gradual and under the supervision of a healthcare provider. Reduction in corticosteroid dose may be associated with systemic withdrawal symptoms and/or unmask conditions previously suppressed by systemic corticosteroid therapy.

Parasitic (Helminth) Infection
Patients with pre-existing helminth infections should be treated for their infection prior to initiation of EXDENSUR therapy. If patients become infected while receiving EXDENSUR and do not respond to anti-helminth treatment, discontinue EXDENSUR until the infection resolves.

ADVERSE REACTIONS

In patients receiving EXDENSUR, the most common adverse reactions (≥4%) were upper respiratory tract infection, allergic rhinitis, influenza, arthralgia, and pharyngitis. Injection site reactions have also occurred. 

USE IN SPECIFIC POPULATIONS

The data in pregnant women are insufficient to identify a drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes. Transport of endogenous IgG antibodies and monoclonal antibodies, such as depemokimab-ulaa, across the placenta increases as pregnancy progresses and peaks during the third trimester.

EXDENSUR can cross the placenta during pregnancy and the presence of the YTE modification may prolong and increase exposure to the infant exposed in utero. The impact of transmission to the fetus should be considered. Pregnant women exposed to EXDENSUR, or their healthcare providers, should report EXDENSUR exposure by calling 1-888-825-5249.

Please see full Prescribing Information for EXDENSUR.

To report SUSPECTED ADVERSE REACTIONS, contact GSK at gsk.public.reportum.com or 1-888-825-5249 or
FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

References

  1. Heaney LG, Perez de Llano L, Al-Ahmad M, et al. Eosinophilic and noneosinophilic asthma: an expert consensus framework to characterize phenotypes in a global real-life severe asthma cohort. Chest. 2021;160(3):814-830.

  2. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention, 2025. Updated November 2025. Available at: https://ginasthma.org/2025-gina-strategy-report/. Accessed December 17, 2025.

  3. Price DB, Bosnic-Anticevich S, Pavord ID, et al. Association of elevated fractional exhaled nitric oxide concentration and blood eosinophil count with severe asthma exacerbations. Clin Transl Allergy. 2019;9(41):1-18.

  4. Wang E, Weschler ME, Tran TN, et al. Characterization of severe asthma worldwide. Chest. 2020;157:790–804.

  5. Lee LK, Obi E, Paknis B, et al. Asthma control and disease burden in patients with asthma and allergic comorbidities. J Asthma. 2018;55:208–219.

  6. Miller MK, Lee DJ, Miller DP, et al. for the TENOR study group. Recent asthma exacerbations: A key predictor of future exacerbations. Respir Med. 2007;101(3):481-489.